GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy

E-ISSN： 2212-3938|7|3|214-228

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.7, Iss.3, 2012-08, pp. : 214-228

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging GLP-1 receptor agonists

By Lund Asger Knop Filip K Vilsbøll Tina

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. : 607-618

Informa Healthcare

Access to resources Recommend Favorite

Novel GLP-1 receptor agonists for diabetes

By Garber Alan J

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 45-57

Informa Healthcare

Access to resources Recommend Favorite

Safety and adverse effects associated with GLP-1 analogues

By Stephens Jeffrey W Bain Stephen C

Expert Opinion on Drug Safety, Vol. 6, Iss. 4, 2007-07 ,pp. : 417-422

Informa Healthcare

Access to resources Recommend Favorite

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

By Parkes David G Mace Kenneth F Trautmann Michael E

Expert Opinion on Drug Discovery, Vol. 8, Iss. 2, 2013-02 ,pp. : 219-244

Informa Healthcare

Access to resources Recommend Favorite

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

By Briones Mariele Bajaj Mandeep

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 1055-1064

Informa Healthcare

Access to resources Recommend Favorite